Education
About Us
Working with TipRanks
Follow Us
Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
DNTH Stock Chart & Stats
$77.76
$0.37(1.44%)
At close: 4:00 PM EST
$77.76
$0.37(1.44%)
Day’s Range― - ―
52-Week Range$13.37 - $88.02
Previous CloseN/A
Volume29.07K
Average Volume (3M)1.00M
Market Cap
$3.46B
Enterprise Value$2.77B
Total Cash (Recent Filing)$404.30M
Total Debt (Recent Filing)$1.39M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
May 07, 2026EPS Estimate
-1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.43
Shares Outstanding44,471,092
10 Day Avg. Volume588,847
30 Day Avg. Volume1,003,841
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)3.16
Price to Sales (P/S)764.98
P/FCF Ratio-12.05
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue1.36K
Enterprise Value/Gross Profit1.36K
Enterprise Value/Ebitda-15.91
Forecast
1Y Price Target
$123.77Price Target Upside59.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-4.25
Revenue Forecast (FY)$1.63M
Bulls Say, Bears Say
Bulls Say
Development Strategy And Patient ConveniencePrioritizing an autoinjector-compatible lower dose and simplifying the regimen to a single subcutaneous dose improves patient convenience and may accelerate adoption and competitive positioning versus higher-dose alternatives.
EfficacyInterim responder analysis in the CAPTIVATE trial showed a majority of patients achieved clinically meaningful improvement, supporting the potential for claseprubart to become a frontline therapy in CIDP.
Safety ProfileClinical data reported no drug-related serious adverse events, no autoimmune activation, and no serious infections, which supports a favorable safety profile and should reduce prescriber and regulator hesitation.
Bears Say
Financial And Cash Runway RiskHigher projected operating expenses to support multiple late-stage programs combined with a limited cash runway could increase cash burn and create financing pressure.
Small Sample Size And Clinical RiskInterim results were based on a small patient cohort, limiting confidence in the efficacy signal and increasing the risk that larger trials may not replicate early responder rates.
Trial Design And Pivotal ValidationSubstantial reductions in initial trial enrollment shrink the pool of responders for the randomized withdrawal phase, potentially complicating regulatory validation and statistical robustness.
Dianthus Therapeutics News
DNTH FAQ
What was Dianthus Therapeutics’s price range in the past 12 months?
Dianthus Therapeutics lowest stock price was $13.37 and its highest was $88.02 in the past 12 months.
What is Dianthus Therapeutics’s market cap?
Dianthus Therapeutics’s market cap is $3.46B.
When is Dianthus Therapeutics’s upcoming earnings report date?
Dianthus Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 45 days.
How were Dianthus Therapeutics’s earnings last quarter?
Dianthus Therapeutics released its earnings results on Mar 09, 2026. The company reported -$1.43 earnings per share for the quarter, missing the consensus estimate of -$1.006 by -$0.424.
Is Dianthus Therapeutics overvalued?
According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued.
Does Dianthus Therapeutics pay dividends?
Dianthus Therapeutics does not currently pay dividends.
What is Dianthus Therapeutics’s EPS estimate?
Dianthus Therapeutics’s EPS estimate is -1.06.
How many shares outstanding does Dianthus Therapeutics have?
Dianthus Therapeutics has 44,471,092 shares outstanding.
What happened to Dianthus Therapeutics’s price movement after its last earnings report?
Dianthus Therapeutics reported an EPS of -$1.43 in its last earnings report, missing expectations of -$1.006. Following the earnings report the stock price went up 21.518%.
Which hedge fund is a major shareholder of Dianthus Therapeutics?
Currently, no hedge funds are holding shares in DNTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dianthus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$123.77 (59.17% Upside)
$123.77 (59.17% Upside)
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 18.7%
Last 30 Days ▲ 18.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.18%
12-Months-Change
Fundamentals
Return on Equity
-28.57%
Trailing 12-Months
Asset Growth
-11.62%
Trailing 12-Months
Company Description
Dianthus Therapeutics
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
DNTH Stock 12 Month Forecast
Average Price Target
$123.77
▲(59.17% Upside)
Technical Analysis
Ardelyx
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Amylyx Pharmaceuticals Inc
―
Biohaven Ltd.
―
Ownership Overview
0.15% Insiders
21.44% Mutual Funds
50.16% Other Institutional Investors
18.29% Public Companies and Individual Investors
Options Prices
Currently, No data available
---